Display options
Cite
Strasser AA, Souprountchouk V, Kaufmann A, et al. Nicotine Replacement, Topography, and Smoking Phenotypes of E-cigarettes. Tob Regul Sci. 2016;2(4):352-362doi: 10.18001/TRS.2.4.7.
Strasser, A. A., Souprountchouk, V., Kaufmann, A., Blazekovic, S., Leone, F., Benowitz, N. L., & Schnoll, R. A. (2016). Nicotine Replacement, Topography, and Smoking Phenotypes of E-cigarettes. Tobacco regulatory science, 2(4), 352-362. https://doi.org/10.18001/TRS.2.4.7
Strasser, Andrew A, et al. "Nicotine Replacement, Topography, and Smoking Phenotypes of E-cigarettes." Tobacco regulatory science vol. 2,4 (2016): 352-362. doi: https://doi.org/10.18001/TRS.2.4.7
Strasser AA, Souprountchouk V, Kaufmann A, Blazekovic S, Leone F, Benowitz NL, Schnoll RA. Nicotine Replacement, Topography, and Smoking Phenotypes of E-cigarettes. Tob Regul Sci. 2016 Oct;2(4):352-362. doi: 10.18001/TRS.2.4.7. PMID: 27942543; PMCID: PMC5142626.
Copy Download .nbib Format: NLM
Share it on

Tob Regul Sci. 2016 Oct;2(4):352-362. doi: 10.18001/TRS.2.4.7.

Nicotine Replacement, Topography, and Smoking Phenotypes of E-cigarettes.

Tobacco regulatory science

Andrew A Strasser, Valentina Souprountchouk, Amanda Kaufmann, Sonja Blazekovic, Frank Leone, Neal L Benowitz, Robert A Schnoll

Affiliations

  1. Department of Psychiatry, University of Pennsylvania, Philadelphia, PA.
  2. Pulmonary, Allergy, & Critical Care Division, University of Pennsylvania Presbyterian Medical Center, Philadelphia, PA.
  3. Division of Clinical Pharmacology and Experimental Therapeutics, Departments of Medicine and Bioengineering & Therapeutic Sciences, University of California-San Francisco, San Francisco, CA.

PMID: 27942543 PMCID: PMC5142626 DOI: 10.18001/TRS.2.4.7

Abstract

OBJECTIVES: Little is known about the degree of nicotine replacement across first-generation e-cigarette brands, how e-cigarettes are used, and if there is variation across brands in relevant smoking phenotypes. The objective of this project was to collect data that are critical to better understanding, use, and exposure when using e-cigarettes, which may then inform clinical trials and tobacco regulatory policy.

METHODS: Twenty-eight cigarette smokers were randomized to use one of 5 popular brands of e-cigarettes for a 10-day study. Day 1 (own cigarette brand) data established baseline levels for cotinine, carbon monoxide (CO), topography, cigarette liking, withdrawal, and craving. Participants returned on Days 5 and 10 to reassess these measures while exclusively using e-cigarettes.

RESULTS: Compared to cigarette smoking, e-cigarettes provided significantly lower nicotine levels (25%-50%), reduced CO exposure, and lower ratings of liking (p < .05). Topography significantly differed between cigarette and e-cigarette sessions (p < .05). All brands significantly reduced withdrawal and craving (p < .05). There were no significant brand differences in outcome measures associated with exposure or use.

CONCLUSIONS: E-cigarettes are not liked as much as cigarettes, provide significantly lower nicotine replacement, reduce CO exposure, and mitigate withdrawal and craving. The patterns of use significantly differ compared to cigarette smoking.

Keywords: cotinine; e-cigarette; nicotine craving; nicotine withdrawal; smoking behavior; vaping

References

  1. MMWR Morb Mortal Wkly Rep. 2014 Jun 27;63(25):542-7 - PubMed
  2. Tob Control. 2010 Feb;19(1):87-8 - PubMed
  3. Nicotine Tob Res. 2002 May;4(2):149-59 - PubMed
  4. Tob Control. 2014 Mar;23(2):133-9 - PubMed
  5. Tob Control. 2011 Jan;20(1):47-52 - PubMed
  6. Biol Mass Spectrom. 1991 May;20(5):247-52 - PubMed
  7. Addict Behav. 2015 Sep;48:1-4 - PubMed
  8. Nicotine Tob Res. 2015 Oct;17 (10 ):1187-94 - PubMed
  9. Drug Alcohol Depend. 2016 Aug 1;165:245-52 - PubMed
  10. MMWR Morb Mortal Wkly Rep. 2014 Jan 17;63(2):29-34 - PubMed
  11. Tob Control. 2011 May;20(3):243-8 - PubMed
  12. Am J Prev Med. 2014 Oct;47(4):476-80 - PubMed
  13. Nicotine Tob Res. 2013 Sep;15(9):1623-7 - PubMed
  14. Br J Addict. 1991 Nov;86(11):1467-76 - PubMed
  15. Psychol Addict Behav. 2016 Feb;30(1):101-5 - PubMed
  16. Nicotine Tob Res. 2010 Sep;12(9):905-12 - PubMed
  17. Br J Addict. 1991 Sep;86(9):1119-27 - PubMed
  18. Addict Behav. 1984;9(4):409-12 - PubMed
  19. Tob Control. 2016 Apr;25(e1):e3-5 - PubMed
  20. Tob Control. 2014 Jul;23 Suppl 3:iii3-9 - PubMed
  21. Nicotine Tob Res. 2015 Feb;17(2):142-9 - PubMed
  22. Cancer Epidemiol Biomarkers Prev. 2013 Mar;22(3):382-9 - PubMed
  23. Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1125-33 - PubMed
  24. Respir Care. 2008 Sep;53(9):1217-22 - PubMed
  25. Sci Rep. 2014 Feb 26;4:4133 - PubMed
  26. JAMA. 2015 Aug 18;314(7):700-7 - PubMed
  27. Nicotine Tob Res. 2015 Feb;17(2):259-69 - PubMed
  28. Cochrane Database Syst Rev. 2012 Oct 17;10:CD008286 - PubMed
  29. Exp Clin Psychopharmacol. 2009 Dec;17(6):405-12 - PubMed
  30. Int J Environ Res Public Health. 2013 Jun 18;10(6):2500-14 - PubMed
  31. Am J Public Health. 2010 Dec;100(12):2340-2 - PubMed
  32. Nicotine Tob Res. 2006 Dec;8(6):727-38 - PubMed
  33. Cancer Epidemiol Biomarkers Prev. 2010 Aug;19(8):1945-53 - PubMed
  34. Tob Control. 2014 May;23 Suppl 2:ii23-9 - PubMed
  35. Nicotine Tob Res. 2015 Oct;17 (10 ):1279-83 - PubMed
  36. Nicotine Tob Res. 2015 Oct;17 (10 ):1242-6 - PubMed

Publication Types

Grant support